Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hermanski-Pudlak Syndrome | 7 | 2024 | 16 | 2.180 |
Why?
|
| Bivalvia | 11 | 2022 | 28 | 1.890 |
Why?
|
| Hemoglobins | 13 | 2022 | 113 | 1.750 |
Why?
|
| Repressor Proteins | 6 | 2023 | 273 | 1.730 |
Why?
|
| Albinism, Oculocutaneous | 4 | 2024 | 6 | 1.560 |
Why?
|
| Monophenol Monooxygenase | 3 | 2024 | 14 | 1.310 |
Why?
|
| Mutation | 12 | 2024 | 1177 | 1.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 41 | 0.790 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 333 | 0.780 |
Why?
|
| Carrier Proteins | 4 | 2018 | 321 | 0.650 |
Why?
|
| Puerto Rico | 16 | 2023 | 1413 | 0.630 |
Why?
|
| Sulfides | 3 | 2022 | 78 | 0.620 |
Why?
|
| Warfarin | 8 | 2016 | 67 | 0.610 |
Why?
|
| Heterozygote | 5 | 2024 | 110 | 0.610 |
Why?
|
| Membrane Proteins | 3 | 2014 | 561 | 0.550 |
Why?
|
| Genetic Testing | 5 | 2024 | 91 | 0.540 |
Why?
|
| Evolution, Molecular | 2 | 2022 | 307 | 0.540 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 7 | 2015 | 51 | 0.540 |
Why?
|
| Oxygen | 5 | 2022 | 218 | 0.530 |
Why?
|
| Histones | 1 | 2018 | 197 | 0.520 |
Why?
|
| RNA, Messenger | 5 | 2018 | 1271 | 0.490 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 11 | 0.490 |
Why?
|
| Focal Dermal Hypoplasia | 2 | 2014 | 2 | 0.470 |
Why?
|
| Anticoagulants | 8 | 2016 | 122 | 0.460 |
Why?
|
| Skin Diseases | 2 | 2014 | 30 | 0.460 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 81 | 0.450 |
Why?
|
| Iris Diseases | 1 | 2014 | 2 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 186 | 0.430 |
Why?
|
| Retinal Diseases | 1 | 2014 | 20 | 0.420 |
Why?
|
| Strabismus | 1 | 2014 | 18 | 0.420 |
Why?
|
| Hydrogen Sulfide | 5 | 2016 | 77 | 0.420 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2013 | 20 | 0.410 |
Why?
|
| Transcriptional Activation | 2 | 2011 | 173 | 0.410 |
Why?
|
| Vision Disorders | 1 | 2014 | 61 | 0.410 |
Why?
|
| Fibroblasts | 3 | 2023 | 281 | 0.410 |
Why?
|
| Amino Acid Sequence | 10 | 2022 | 1180 | 0.390 |
Why?
|
| Gene Expression Regulation | 3 | 2023 | 1070 | 0.390 |
Why?
|
| Humans | 34 | 2024 | 43102 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 968 | 0.370 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 201 | 0.360 |
Why?
|
| Mixed Function Oxygenases | 5 | 2012 | 31 | 0.360 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2011 | 13 | 0.350 |
Why?
|
| Base Sequence | 5 | 2018 | 983 | 0.350 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 376 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 83 | 0.340 |
Why?
|
| Hemoglobin, Sickle | 1 | 2010 | 11 | 0.340 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2010 | 5 | 0.340 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 592 | 0.320 |
Why?
|
| Erythrocytes | 1 | 2010 | 126 | 0.310 |
Why?
|
| Molecular Sequence Data | 8 | 2016 | 1542 | 0.310 |
Why?
|
| Proteins | 1 | 2012 | 382 | 0.310 |
Why?
|
| Escherichia coli | 4 | 2015 | 460 | 0.310 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 652 | 0.300 |
Why?
|
| Cloning, Molecular | 5 | 2015 | 314 | 0.290 |
Why?
|
| Child | 7 | 2023 | 3443 | 0.290 |
Why?
|
| Ectodermal Dysplasia | 3 | 2021 | 5 | 0.290 |
Why?
|
| Poly A | 1 | 2008 | 33 | 0.270 |
Why?
|
| Folic Acid | 2 | 2011 | 49 | 0.270 |
Why?
|
| DNA, Complementary | 2 | 2008 | 196 | 0.260 |
Why?
|
| Pedigree | 3 | 2024 | 94 | 0.260 |
Why?
|
| Hemorrhage | 2 | 2019 | 55 | 0.250 |
Why?
|
| Exons | 2 | 2018 | 92 | 0.240 |
Why?
|
| Binding Sites | 3 | 2023 | 671 | 0.240 |
Why?
|
| Homozygote | 5 | 2015 | 77 | 0.220 |
Why?
|
| Sequence Alignment | 5 | 2016 | 272 | 0.220 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 704 | 0.220 |
Why?
|
| Genotype | 7 | 2016 | 800 | 0.220 |
Why?
|
| Tyrosine | 3 | 2014 | 120 | 0.220 |
Why?
|
| Animals | 15 | 2022 | 16992 | 0.210 |
Why?
|
| Adult | 11 | 2024 | 13872 | 0.200 |
Why?
|
| Female | 17 | 2019 | 24698 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 455 | 0.190 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2002 | 3 | 0.190 |
Why?
|
| Erythrocyte Volume | 1 | 2002 | 4 | 0.190 |
Why?
|
| Hemeproteins | 3 | 2015 | 15 | 0.180 |
Why?
|
| Infant, Newborn | 5 | 2011 | 972 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2002 | 2 | 0.180 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 3 | 0.180 |
Why?
|
| Pharmacogenetics | 3 | 2015 | 67 | 0.180 |
Why?
|
| Male | 14 | 2016 | 23409 | 0.180 |
Why?
|
| Codon, Nonsense | 2 | 2011 | 23 | 0.170 |
Why?
|
| Incidence | 1 | 2023 | 1078 | 0.160 |
Why?
|
| Computational Biology | 1 | 2022 | 327 | 0.160 |
Why?
|
| Heme | 5 | 2009 | 72 | 0.160 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 100 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 200 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2013 | 1546 | 0.150 |
Why?
|
| Wetlands | 1 | 2018 | 15 | 0.140 |
Why?
|
| Phylogeny | 2 | 2022 | 769 | 0.140 |
Why?
|
| Conserved Sequence | 1 | 2018 | 122 | 0.140 |
Why?
|
| Aged | 7 | 2016 | 8214 | 0.140 |
Why?
|
| Aspergillus | 1 | 2018 | 14 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 98 | 0.140 |
Why?
|
| Antibodies, Fungal | 1 | 2018 | 24 | 0.140 |
Why?
|
| Antigens, Fungal | 1 | 2018 | 34 | 0.140 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 61 | 0.140 |
Why?
|
| Algorithms | 3 | 2016 | 509 | 0.140 |
Why?
|
| Mutation, Missense | 2 | 2015 | 91 | 0.130 |
Why?
|
| Allergens | 1 | 2018 | 65 | 0.130 |
Why?
|
| Mollusca | 2 | 2008 | 17 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 515 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 296 | 0.120 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2016 | 31 | 0.120 |
Why?
|
| Blotting, Northern | 2 | 2008 | 150 | 0.120 |
Why?
|
| Visual Acuity | 2 | 2014 | 111 | 0.120 |
Why?
|
| Thrombosis | 1 | 2016 | 81 | 0.110 |
Why?
|
| Middle Aged | 8 | 2016 | 12222 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 310 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2544 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2018 | 883 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2016 | 142 | 0.110 |
Why?
|
| Eye Color | 1 | 2014 | 3 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 122 | 0.110 |
Why?
|
| United States | 2 | 2023 | 5205 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 95 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 94 | 0.100 |
Why?
|
| Adolescent | 5 | 2014 | 6081 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 526 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 34 | 0.100 |
Why?
|
| Gene Expression | 1 | 2016 | 701 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 114 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 127 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 196 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1124 | 0.090 |
Why?
|
| Cathepsin B | 1 | 2012 | 35 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 863 | 0.090 |
Why?
|
| Kinetics | 4 | 2006 | 695 | 0.090 |
Why?
|
| Malabsorption Syndromes | 1 | 2011 | 3 | 0.090 |
Why?
|
| Reticulocyte Count | 1 | 2010 | 3 | 0.080 |
Why?
|
| Immune System | 1 | 2010 | 41 | 0.080 |
Why?
|
| Neonatal Screening | 1 | 2010 | 25 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 38 | 0.080 |
Why?
|
| Osteogenesis | 1 | 2010 | 57 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2011 | 115 | 0.080 |
Why?
|
| DNA | 2 | 2010 | 592 | 0.080 |
Why?
|
| Muscle Development | 1 | 2010 | 51 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2010 | 49 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2015 | 13 | 0.080 |
Why?
|
| Amino Acid Substitution | 3 | 2009 | 135 | 0.080 |
Why?
|
| Metagenomics | 1 | 2009 | 46 | 0.070 |
Why?
|
| Ferric Compounds | 2 | 2006 | 62 | 0.070 |
Why?
|
| Fovea Centralis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 529 | 0.070 |
Why?
|
| Prognosis | 1 | 2010 | 861 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2010 | 171 | 0.070 |
Why?
|
| Protein Binding | 3 | 2009 | 1082 | 0.070 |
Why?
|
| Alleles | 2 | 2015 | 352 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2015 | 206 | 0.070 |
Why?
|
| Ligands | 2 | 2005 | 388 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1621 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 2853 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 734 | 0.060 |
Why?
|
| HIV-1 | 1 | 2012 | 755 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2006 | 93 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hemostatics | 1 | 2005 | 10 | 0.060 |
Why?
|
| Neurons | 1 | 2012 | 1263 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 104 | 0.050 |
Why?
|
| Apoptosis | 1 | 2012 | 1568 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2004 | 165 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 186 | 0.050 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 140 | 0.050 |
Why?
|
| Codon | 1 | 2003 | 39 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 313 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 5080 | 0.050 |
Why?
|
| Prevalence | 3 | 2015 | 1612 | 0.050 |
Why?
|
| Spectrum Analysis, Raman | 3 | 2009 | 95 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 780 | 0.050 |
Why?
|
| Infant | 1 | 2006 | 1175 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2002 | 11 | 0.050 |
Why?
|
| Alanine | 1 | 2002 | 34 | 0.050 |
Why?
|
| Valine | 1 | 2002 | 29 | 0.050 |
Why?
|
| Protein Conformation | 2 | 2015 | 416 | 0.050 |
Why?
|
| Risk | 1 | 2002 | 287 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 1759 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 118 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 87 | 0.030 |
Why?
|
| Ferrous Compounds | 2 | 2009 | 22 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2008 | 144 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 280 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 458 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 4 | 0.030 |
Why?
|
| Membrane Fusion Proteins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Pregnancy | 1 | 2002 | 1772 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 63 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 19 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 43 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2016 | 79 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 195 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 29 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2005 | 83 | 0.030 |
Why?
|
| Crystallography | 1 | 2014 | 8 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 90 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 760 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 23 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 97 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1285 | 0.030 |
Why?
|
| Hydrogen Peroxide | 2 | 2006 | 190 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2006 | 388 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 259 | 0.030 |
Why?
|
| Cystatin B | 1 | 2012 | 11 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2012 | 21 | 0.020 |
Why?
|
| Cystatin C | 1 | 2012 | 25 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2012 | 37 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 408 | 0.020 |
Why?
|
| Lysosomes | 1 | 2012 | 86 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 166 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 490 | 0.020 |
Why?
|
| Facies | 1 | 2010 | 4 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2010 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 73 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 199 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 277 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 109 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 43 | 0.020 |
Why?
|
| Electron Transport | 1 | 2009 | 47 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 169 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 64 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 74 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 594 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 207 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1600 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 473 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sulfites | 1 | 2008 | 13 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2007 | 7 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 25 | 0.020 |
Why?
|
| Dimerization | 1 | 2008 | 112 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 38 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 506 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2008 | 280 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1035 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 876 | 0.020 |
Why?
|
| Cyanides | 1 | 2005 | 14 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 47 | 0.010 |
Why?
|
| Water | 1 | 2008 | 316 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2005 | 5 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2676 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 423 | 0.010 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 7 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 204 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 251 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 518 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 3156 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1604 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 6644 | 0.010 |
Why?
|